Menu Search
Equities

Barinthus Biotherapeutics PLC

2AB:MUN

Barinthus Biotherapeutics PLC

Actions
  • Price (EUR)1.12
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-58.52%
  • Beta--
Data delayed at least 15 minutes, as of Sep 26 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Its pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells and guide them towards a healthy balance. It is focused on developing two key product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease.

  • Revenue in USD (TTM)0.00
  • Net income in USD-63.79m
  • Incorporated2021
  • Employees130.00
  • Location
    Barinthus Biotherapeutics PLCThe Schrdinger BuildingHeatley Road, The Oxford Science ParkDIDCOT OX11 0DFUnited KingdomGBR
  • Phone+44 186 581 8808
  • Websitehttps://www.barinthusbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.